Researchers Identified New Driver of Lung Cancer Resistance
A study found that targeting pyruvate carboxylase could improve the efficacy of KRAS G12C inhibitors in specific lung tumors.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Does new research into cancer treatment mechanisms make you more optimistic about future medical outcomes?
Scientists have identified pyruvate carboxylase as a key factor in how certain lung cancers resist targeted therapies. The metabolic enzyme helps tumor cells maintain essential nutrient pools when treated with KRAS G12C inhibitors.
Why it matters
KEAP1-mutant lung cancers often prove difficult to treat due to their ability to rewire internal metabolism. Blocking this survival mechanism could offer a new strategy to prevent resistance and improve outcomes for patients with specific tumor profiles.
The study utilized KEAP1 and STK11 co-mutant tumor models to demonstrate how NRF2 activation drives pyruvate carboxylase expression. Researchers observed that this enzyme channels glucose carbon into the TCA cycle to support vital aspartate synthesis.
The details
The loss of KEAP1 function creates a metabolic dependence on pyruvate carboxylase to synthesize nucleotides during inhibitor treatment. By genetically ablating this enzyme, researchers effectively suppressed tumor growth and restored sensitivity to KRAS G12C therapies.
Timeline
The findings were published on October 2, 2026.
The Big Picture
This study shifts the trajectory of KRAS G12C inhibitor development pipelines by introducing metabolic inhibition as a necessary combination therapy. It challenges the prior focus on purely genetic targets by highlighting the essential role of enzyme-driven metabolic plasticity.
This research provides a potential roadmap for developing future combination drug therapies that may prevent cancer cells from becoming resistant to treatment. It offers long-term hope for more durable responses to targeted therapies for patients with KEAP1-mutant lung cancers.
The takeaway
Understanding how cancer cells reroute their metabolism is critical for designing therapies that do not lose their impact over time. Combining targeted pathway inhibitors with metabolic interference may be the next standard approach to overcoming drug resistance.
Further reading
For more on advancements in oncology, visit the Cancer section.
Source note: This article includes information reported by Nature.
Live Poll
Does new research into cancer treatment mechanisms make you more optimistic about future medical outcomes?
